ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
The Company unveils brand name for its planned minoxidil hair regrowth product
该公司公布了计划中的米诺地尔头发再生产品的品牌名称
LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that the company has recently submitted their application for their planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and we expect this process to be completed within a few weeks.
洛杉矶，2023年3月16日（GLOBE NEWSWIRE）——ViaDerma, Inc.（场外交易链接：VDRM）欣然宣布，该公司最近提交了计划中的米诺地尔头发再生产品的申请，以获得美国食品药品管理局的注册资格。FDA的注册过程应该相对较快，我们预计该过程将在几周内完成。
The company has chosen Nupelo as the brand name for its new hair regrowth product. Nupelo will incorporate ViaDerrma's proprietary, patent-pending dual carrier transdermal delivery technology and use Minoxidil (topical route) in their new hair regrowth product.
该公司选择Nupelo作为其新的头发再生产品的品牌名称。Nupelo将采用ViaDerrma专有的、正在申请专利的双载体透皮给药技术，并在其新的头发再生产品中使用Minoxidil（局部疗程）。
ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023.
ViaDerma计划通过多个在线平台让Nupelo可供购买，包括他们新收购的域名nupelo.com。该产品预计将于2023年第二季度末准备上市，并可在网上购买。
"Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both," said ViaDerma's President & CEO, Dr. Chris Otiko.
“一切都非常快速、顺利地融合在一起。由于我们专有的透皮给药系统的极其有效，我们能够在很短的时间内开发出像Nupelo这样的新产品。许多其他护发产品只能减少脱发，但在实际再生头发方面却无效。Nupelo努力解决这两个问题，” ViaDerma总裁兼首席执行官克里斯·奥蒂科博士说。
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit:
关于 ViaDerma, Inc.
ViaDerma, Inc.（场外交易代码：VDRM）是一家上市的专业制药公司，致力于将新产品推向市场，并将其创新技术许可给制药行业各个治疗领域的现任领导者。欲了解更多信息，请访问：
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management's beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
根据证券法，任何对未来表现的预测都是 “前瞻性陈述”。纳入此类陈述是为了让潜在投资者有机会了解管理层对未来的信念和看法，这样他们就可以将这些信念和观点用作评估投资的众多因素之一。
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter:
Follow ViaDerma on Facebook:
联系信息：
投资者关系
电子邮件：ir@viaderma.com
电话：310-734-6111
在推特上关注 ViaDerma：
在 Facebook 上关注 ViaDerma：